Skip to main content
SpringerLink
Log in

Cardiorenal Continuum

  • Chapter
Cardiorenal Syndrome

  • 1127 Accesses

Abstract

Atherosclerosis underlies the vast majority of vascular conditions that are a leading cause of death and serious morbidity or disabilities worldwide. Cardiovascular events rarely occur in patients without underlying disease; rather, they typically take place as the final stage of a pathophysiological process that results in progressive vascular damage, including vital organ damage—specifically, the kidney and the heart. A large percentage of patients attended at the clinic and admitted to hospital have various degrees of heart and kidney dysfunction. Disorders affecting one of them mostly involve the other. Such interactions represent the pathogenesis for a clinical condition called cardiorenal syndrome. Renal and cardiovascular diseases share the same etiopathogenic risk factors. If these factors are controlled, then atherosclerotic process evolution and further target-organ damage or cardiovascular events can be prevented. As the cardiorenal process advances, atherosclerotic vascular damage progresses, and subclinical organ damage can be detected. Chronic kidney disease is included at this stage, and a number of conditions associated with renal dysfunction become novel risk factors that may accelerate vascular damage

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wolf-Maier K, Cooper RS, Banegas JR et al (2003) Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289(18):2363–2369

    Article  PubMed  Google Scholar 

  2. Banegas JR, Rodriguez-Artalejo F, Ruilope LM et al (2002) Hypertension magnitude and management in the elderly population of Spain. J Hypertens 20(11):2157–2164

    Article  CAS  PubMed  Google Scholar 

  3. Wang TJ, Evans JC, Meigs JB et al (2005) Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 111(11):1370–1376

    Article  CAS  PubMed  Google Scholar 

  4. Cowley AW Jr, Roman RJ (1996) The role of the kidney in hypertension. JAMA 275(20):1581–1589

    Article  PubMed  Google Scholar 

  5. Mogensen CE. (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310(6):356–360

    Article  CAS  PubMed  Google Scholar 

  6. Dzau VJ, Antman EM, Black HR et al (2006) The CV disease continuum validated: clinical evidence of improved patient outcomes: part II: clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation 114:2871–2891

    Article  PubMed  Google Scholar 

  7. Olsen MH, Wachtell K, Ibsen H et al (2006) LIFE study investigators. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 24:775–781

    Article  CAS  PubMed  Google Scholar 

  8. Ruilope L, Kjeldsen SE, de la Sierra A et al (2007) The kidney and CV risk—implications for management: a consensus statement from the European Society of Hypertension. Blood Press 16(2):72–79

    Article  PubMed  Google Scholar 

  9. Keane WF (2001) Metabolic pathogenesis of cardiorenal disease. Am J Kidney Dis 38(6):1372–1375

    Article  CAS  PubMed  Google Scholar 

  10. Ruggenenti P, Perna A, Ganeva M et al (2004) Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351(19):1941–1951

    Article  CAS  PubMed  Google Scholar 

  11. Haller H, Viberti GC, Mimran A et al (2006) Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 24:403–408

    Article  CAS  PubMed  Google Scholar 

  12. Sjølie AK, Porta M, Parving HH et al (2005) The DIRECT Programme Study Group. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J Renin Angiotensin Aldosterone Syst 6(1):25–32

    Article  PubMed  Google Scholar 

  13. Julius S, Kjeldsen SE, Weber M et al (2004) VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022–2031

    Article  CAS  PubMed  Google Scholar 

  14. Lithell H, Hansson L, Skoog I et al (2003) SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 21:875–886

    Article  CAS  PubMed  Google Scholar 

  15. Hansson L, Lindholm LH, Niskanen L et al (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611–616

    Article  CAS  PubMed  Google Scholar 

  16. Hansson L, Hedner T, Lund-Johansen P et al (2000) Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356:359–365

    Article  CAS  PubMed  Google Scholar 

  17. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288:2981–2997

    Article  Google Scholar 

  18. The ONTARGET/TRANSCEND investigators (2004) Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE-I-Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148:52–61

    Article  Google Scholar 

  19. Battershill AJ, Scott LJ (2006) Telmisartan: a review of its use in the management of hypertension. Drug 66:51–83

    Article  CAS  Google Scholar 

  20. Yusuf S, Sleight P, Pogue J et al (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145–153

    Article  CAS  PubMed  Google Scholar 

  21. The ONTARGET investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559

    Article  Google Scholar 

  22. Julius S, Nesbitt SD, Egan BM et al (2006) Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354:1685–1697

    Article  CAS  PubMed  Google Scholar 

  23. Sever PS, Dahlof B, Poulter NR et al (2003) ASCOT investigators. The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet 361:1149–1158

    Article  CAS  PubMed  Google Scholar 

  24. Jamerson K, Weber MA, Bakris GL et al (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 359(23):2417–28

    Article  CAS  PubMed  Google Scholar 

  25. Chobanian A, Bakris GL, Black HR et al (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289:2560–2572

    Article  CAS  PubMed  Google Scholar 

  26. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007) Guidelines for the Management of Arterial HypertensionJ Hypertens 25:1105–1187

    Google Scholar 

  27. Tonelli M, Wiebe M, Culleton B et al (2006) Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17:2034–2047

    Article  PubMed  Google Scholar 

  28. Hallan S, Asberg A, Lindberg M, Johnsen H (2004) Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 44:84–93

    Article  PubMed  Google Scholar 

  29. Moe S, Drueke T, Cunningham J et al (2005) Kidney Disease: Improving Global Outcomes (KDIGO). Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67:2089–2100.

    Article  Google Scholar 

  30. Cockroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    Article  Google Scholar 

  31. Ruilope LM, Zanchetti A, Julius S et al; for the VALUE Investigators (2007) Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens 25:1473–1479

    Article  CAS  PubMed  Google Scholar 

  32. Shlipak MG, Katz R, Sarnak MJ et al (2006) Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145:237–246

    CAS  PubMed  Google Scholar 

  33. Parving HH (1996) Initiation and progression of diabetic nephropathy. N Engl J Med 335:1682–1683

    Article  CAS  PubMed  Google Scholar 

  34. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. (1997) Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 314(7083):783–788

    CAS  PubMed  Google Scholar 

  35. Redon J, Williams B (2002) Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 20:353–355

    Article  CAS  PubMed  Google Scholar 

  36. Hillege HL, Fidler V, Diercks GF et al (2002) Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777–1782.

    Article  CAS  PubMed  Google Scholar 

  37. Arnlov J, Evans JC, Meigs JB et al (2005) Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112:969–975

    Article  PubMed  Google Scholar 

  38. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE (1990) Microalbuminuria as predictor of increased mortality in elderly people. BMJ 300:297–300

    Article  CAS  PubMed  Google Scholar 

  39. Gerstein HC, Mann JF, Yi Q et al HOPE study investigators (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA 286:421–426

    Article  CAS  PubMed  Google Scholar 

  40. Agewall S, Wikstrand J, Ljungman S, Fagerberg B (1997) Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol 80:164–169

    Article  CAS  PubMed  Google Scholar 

  41. Sarafidis PA, Bakris GL (2006) Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant 21(9):2366–2374

    Article  PubMed  Google Scholar 

  42. Segura J, Ruilope LM (2005) Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk. Fundam Clin Pharmacol 19(4):429–437

    Article  CAS  PubMed  Google Scholar 

  43. Elsayed E F, Tighiouart H, Griffith J (2007) Cardiovascular disease and subsequent kidney disease. Arch Intern Med 167:1130–1136

    Article  CAS  PubMed  Google Scholar 

  44. Ruilope LM, Lahera V, Rodicio JL et al (1994) Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans? Hypertension 23:3–9

    CAS  PubMed  Google Scholar 

  45. Vlagopoulos PT, Tighiouart H, Weiner DE et al (2005) Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 16(11):3403–3410

    Article  PubMed  Google Scholar 

  46. Moe SM (2006) Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 36(Suppl 2):51–62

    Article  CAS  PubMed  Google Scholar 

  47. Segura J, Campo C, Ruilope LM (2002) How relevant and frequent is the presence of mild renal insufficiency in essential hypertension? J Clin Hypertens (Greenwich) 4:332–336

    Article  Google Scholar 

  48. Weiner DE, Tighiouart H, Amin MG et al (2004) Chronic kidney disease as a risk factor for cardiovascular disease and all cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 15:1307–1315

    Article  PubMed  Google Scholar 

  49. Segura J, Campo C, Gil P et al (2004) Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 15:1616–1622

    Article  PubMed  Google Scholar 

  50. Ruilope LM (2002) The kidney as a sensor of cardiovascular risk in essential hypertension. J Am Soc Nephrol 13:S165–S168

    Article  CAS  PubMed  Google Scholar 

  51. Schiffrin EL, Lipman ML, Mann J (2007) Chronic kidney disease: effects on the cardiovascular system. Circulation 116:85–97

    Article  PubMed  Google Scholar 

  52. Tucker B, Fabbian F, Giles M et al (1997) Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 12:724–728

    Article  CAS  PubMed  Google Scholar 

  53. Wachtell K, Olsen MH, Dahlof B et al (2002) Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 20(3):405–412

    Article  CAS  PubMed  Google Scholar 

  54. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110(1):32–35

    Article  CAS  PubMed  Google Scholar 

  55. Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869

    Article  CAS  PubMed  Google Scholar 

  56. Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860

    Article  CAS  PubMed  Google Scholar 

  57. Heart Outcomes Prevention Evaluation Study investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259

    Article  Google Scholar 

  58. Parving HH, Lehnert H, Brochner-Mortesen J et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878

    Article  CAS  PubMed  Google Scholar 

  59. Feringa HH, Karagiannis SE, Chonchol M et al (2007) Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors. J Am Soc Nephrol 18:1872–1879

    Article  CAS  PubMed  Google Scholar 

  60. Jafar TH, Stark PC, Schmid CH et al (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139(4):244–252

    CAS  PubMed  Google Scholar 

  61. Ruilope LM, Alcazar JM, Hernandez E et al (1994) Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int Suppl 45:171–173

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain

    Josè A. García-Donaire & Luis M. Ruilope

Authors
  1. Josè A. García-Donaire
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis M. Ruilope
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

    Adel E. Berbari

  2. Clinica Medica Department of Clinical Medicine and Prevention, University of Milano-Bicocca San Gerardo Hospital, Monza, Milan, Italy

    Giuseppe Mancia

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Italia

About this chapter

Cite this chapter

García-Donaire, J.A., Ruilope, L.M. (2010). Cardiorenal Continuum. In: Berbari, A.E., Mancia, G. (eds) Cardiorenal Syndrome. Springer, Milano. https://doi.org/10.1007/978-88-470-1463-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-1463-3_5

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-1462-6

  • Online ISBN: 978-88-470-1463-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation